57
Views
2
CrossRef citations to date
0
Altmetric
Original Research

Impact of prostaglandin glaucoma drops on platelet-activating factor action: an in vitro study

, , , &
Pages 3977-3981 | Published online: 07 Dec 2016

Abstract

Aim

The aim of this study was to investigate the effect of different prostaglandin analogs on platelet-activating factor (PAF) levels.

Methods

Three prostaglandin analogs were selected: bimatoprost 0.3 mg/mL, latanoprost 50 μg/mL, and tafluprost 15 μg/mL. Each drug sample was tested for its ability to cause platelet aggregation, which was measured as PAF-induced aggregation, before and after the addition of various concentrations of the examined sample, creating a linear curve of percentage inhibition (ranging from 0% to 100%) versus different concentrations of the sample. The concentration of the sample that inhibited 50% PAF-induced aggregation was calculated based on this curve, and this value was defined as IC50. In addition, the effect of eye drops on PAF metabolism was examined, through an in vitro analysis on PAF basic metabolic enzymes (PAF-cholinephosphotransferase, PAF-acetyl-CoA:1-O-alkyl-sn-glycero-3-phosphocholine acetyltransferase, and PAF-acetylhydrolase).

Results

The IC50 values for Lumigan UD® (bimatoprost 0.3 mg/mL), Monoprost® (latanoprost 50 μg/mL), and Saflutan (tafluprost 15 μg/mL) were 8.7, 0.28, and 1.4 μg/mL, respectively.

Discussion

All three prostaglandin analogs suspended PAF, but bimatoprost induced the most potent inhibition, compared to tafluprost and to the weak effect of latanoprost.

Introduction

Glaucoma is estimated to be the second leading cause of severe vision loss and blindness worldwide, affecting ~60.5 million people and accounting for 2.65% of the population aged >40 years in 2010.Citation1,Citation2 The medical treatment for glaucoma includes prostaglandin analogs, which are approved as the first-line treatment for glaucoma in the European Glaucoma Society guidelines, carbonic anhydrase inhibitors, β-receptor antagonists, adrenergic agonists, and parasympathomimetics.Citation3,Citation4 Prostaglandins are a family of lipid compounds that are derived enzymatically from essential fatty acids, with each containing 20 carbon atoms, including a 5-carbon ring.Citation5 In eye, they are synthesized by the trabecular endothelial and the ciliary muscle cells from membrane phospholipids and arachidonic acid, exhibiting anti-inflammatory action.Citation6,Citation7 They seem to alter both the function and structure of the uveoscleral pathways, inducing extracellular matrix remodeling, widening of the intermuscular spaces, and dissolution of collagens types I and III.Citation8 Besides prostaglandin E2, various inflammatory molecules, including cytokines, cyclooxygenase 2, tumor necrosis factor-alpha, interleukins, platelet-activating factor (PAF), vascular endothelial growth factor, and C-reactive protein have been implicated in the mechanisms of glaucoma, highlighting the role of inflammation in the pathogenesis of the disease.Citation9,Citation10

PAF (1-0-alkyl-2-acetyl-sn-gluceryl-3phosphorylcholine) is a low-molecular phospholipid mediator that is involved in inflammatory process acting on various types of cells through specific receptors. Two metabolic pathways are responsible for PAF secretion: 1) de novo synthesis, where PAF is produced by a lipid intermediate (1-0-alkyl-2-acetyl-sn-glycerol), through the action of the enzyme cholinephosphotransferase (PAF-CPT), converting cytidine diphosphate-choline (CDP-choline) to cytidine monophosphate; and 2) remodeling pathway, which is activated under inflammatory conditions and results in the secretion of PAF from preexisting membrane-bound ether-linked phospholipids through the enzyme acetyl-CoA:1-O-alkyl-sn-glycero-3-phosphocholine acetyltransferase (lyso-PAF-AT), which transfers an acetyl group in the sn-2 position of lyso-PAF.Citation11,Citation12 In the remodeling pathway, when cytosolic phospholipase A2 is activated, it becomes membrane-associated and hydrolyzes the fatty acyl moiety esterified at the sn-2 position of membrane phospholipids. The subsequent release of 2-lyso-phospholipids (1-radylsn-glycero-3-phosphocholine or lyso-choline-containing membrane phospholipids) serves as substrates for the activation of PAF-acetylhydrolase (PAF-AH).Citation13 The latter represents a heterogeneous group of PLA2 that removes sn-2 acetyl group, without affecting normal membrane phospholipids; they are responsible for the hydrolysis, the inactivation, and the concentrations of PAF in plasma and tissues.Citation14

The activation of PAF requires its coupling with its receptor, which is a 7-transmembrane-G-protein-coupled receptor, located in a great variety of cells, including monocytes, lymphocytes, vascular endothelial and smooth muscle cells, renal and mesangial cells, hepatocytes, keratinocytes, and osteoclasts.Citation11,Citation13 The range of cell responses to PAF explains its role in both physiological processes, such as platelet aggregation and secretion, activation of neutrophils and macrophages, and pathological mechanisms, resulting in asthma, systemic or cardiac anaphylaxis, endotoxin-induced shocks, thrombosis, and gastrointestinal ulceration.Citation11 The detection of PAF in ocular tissues, such as iris, ciliary body, retina, and vascular endothelium, confirms its implication in ocular inflammation and blood flow.Citation15

Regarding the inflammatory background of glaucoma and the implication of PAF in the ocular inflammation and in the glaucomatous neuronal damage, the effect of different prostaglandin analogs on PAF levels was investigated.

Materials and methods

Equipment and solutions

The following equipment was used in the present study:

  1. Heraeus® Labofuge® 400R for centrifugations

  2. Supersonic Bandelin Sonopuls HD 2070 sonicator (Heinrichstraze 3–4, Berlin, Germany) for homogenizations (30% of the power)

  3. Rackbeta (Pharmacia, Wallac, Finland) as liquid scintillation counter

  4. Chrono-Log model 400 VS aggregometer (Havertown, PA, USA) to study platelet aggregation.

The eye drops tested in the present study were as follows: Lumigan UD® (bimatoprost 0.3 mg/mL; Allergan Pharmaceuticals Ltd., Westport, Ireland), Monoprost® (latanoprost 50 μg/mL; Laboratoires Thea, Clermont-Ferrand, France), and Saflutan (tafluprost 15 μg/mL; Vianex S.A., Athens, Greece).

Calculation of the inhibitory effects of sample on PAF-induced aggregation

This is an in vitro study, where no human or animal subjects are included, but blood samples was required. The ethics committee of the General Hospital of Athens G. Gennimatas approved the protocol. Because the study was an in vitro one, no patient informed consent was needed. A total of 9 mL of blood was collected from the marginal ear vein of a New Zealand White rabbit and added in 1 mL of an anticoagulant solution of sodium citrate/citric acid. The sample was centrifuged at 630× g for 13 min at 25°C, and the supernatant was subsequently centrifuged at 1,400× g for 20 min at 25°C in order to obtain plasma (rich in platelets). The isolation of plasma and leukocytes from blood samples and the biological assay on washed rabbit platelets were carried out according to the methods described by Moschos et al.Citation16Citation19 The leukocytes were isolated after the sedimentation of the erythrocytes using 3.4 mL of dextran solution (3% dextran in 0.15 M NaCl) for 1 h at room temperature. The homogenates of leukocytes were aliquoted and stored at −80°C after protein determination by using Bradford method.

Briefly, PAF and the examined drug samples were dissolved in 12.5 mg of bovine serum albumin (BSA) per 1 mL of saline. The ability of each selected drug to cause platelet aggregation was estimated by adding various concentrations of each sample into the platelet suspension. The PAF-induced aggregation was calculated at baseline (0% inhibition) and after the addition of the examined samples (in a variety of concentrations), and a linear curve of the percentage inhibition to the concentrations of each sample was created. The concentration of the sample that inhibited 50% of the PAF-induced aggregation was defined as IC50.

Determination of PAF and biosynthetic enzymes activities

The extraction, purification, and determination of PAF were transacted according to the methods described previously.Citation19Citation21 PAF was extracted according to the Bligh–Dyer method and was separated by a thin-layer chromatography (TLC) on silica gel G-coated plates with a development system consisting of chloroform/methanol/acetic acid/water (100:57:16:8, v/v/v/v). The specific activities of PAF-CPT and lyso-PAF-AT were expressed as pmol of produced PAF/min/mg of sample protein present in each assay.

The homogenate of leukocytes, isolated from New Zealand white rabbits, was used to perform the PAF-CPT and lyso PAF-AT activity assays, as described previously.Citation18Citation20,Citation22 The PAF-CPT activity assay was carried out at 37°C for 20 min in a final volume of 200 μL, started by the addition of CDP-choline and stopped by the addition of 0.5 mL of cold methanol after 20 min. The reaction of lyso PAF-AT was carried out at 37°C for 30 min in a final volume of 200 mL, started with the addition of the homogenated sample and was stopped by adding 0.5 mL of cold methanol after 30 min. Plasma PAF-AH was determined in plasma isolated from New Zealand white rabbits by the trichloroacetic acid precipitation method by using [3H] PAF as a substrate.Citation23 Protein concentrations were measured based on BSA as the protein standard (method of Bradford).Citation17

Statistical analysis

The Statistical Package for the Social Sciences Version 17.0 (SPSS Inc., Chicago, IL, USA) was used for the analysis. The IC50 values were expressed as mean.

Results

The concentration of the bioactive compound that inhibited 50% of the PAF-induced aggregation in the aggregometer cuvette was defined as IC50 and expressed in μg/mL. The IC50 of the tested eye drops indicated that the present substances are considered good inhibitors for PAF, acting in the range of μM. The IC50 values for bimatoprost 0.3 mg/mL, latanoprost 50 μg/mL, and tafluprost 15 μg/mL were 8.7, 0.28, and 1.4 μg/mL, respectively. These values indicated that all tested substances achieved to inhibit PAF.

Discussion

The effect of the three prostaglandins, bimatoprost, latanoprost, and tafluprost, on PAF activity was investigated, evaluating the aggregation of platelets. It was noted that all the three prostaglandins suspended PAF, but bimatoprost induced the most potent inhibition (IC50 =8.7 μg/mL) compared to tafluprost (IC50 =1.4 μg/mL) and to the weak effect of latanoprost (IC50 =0.28 μg/mL). Latanoprost was launched in 1996 and was the first of the currently available topical PGF analogs for glaucoma treatment. It is an esterified prodrug of PGF and, as such, is more lipophilic than the parent compound.Citation24 Bimatoprost is a synthetic structural prostaglandin F analog, where the carboxylic acid is replaced by a neutral ethylamide, but it has low direct effect on prostaglandin F receptors.Citation25 Comparative studies revealed that bimatoprost has a greater hypotonic effect compared to latanoprost, whereas Noecker et al revealed only statistical but not clinical significance of bimatoprost versus latanoprost.Citation26Citation28

Tafluprost, which is the first preservative-free prostaglandin medication developed for the treatment of glaucoma, is a prodrug of synthetic analog of prostaglandin F. It exhibits high affinity and selectivity with prostaglandin F prostanoid receptors, while it also binds to the prostanoid EP3 receptor, amplifying its hypotonic action.Citation29,Citation30 Kurashima et al supported that tafluprost limits ciliary artery contraction, inducing a superior hypotensive effect compared to latanoprost.Citation31 Yamada et al noted that bimatoprost induced greater expression of metalloproteinase 2 (MMP-2) and metalloproteinase 3 (MMP-3) than latanoprost and tafluprost, whereas tafluprost and latanoprost increased the expression MMP-1 and MMP-9, respectively, more than bimatoprost.Citation32 In a previous study, it was found that latanoprost (IC50 =0.29 μM) was found to be the most potent in inhibiting PAF compared to single travoprost (IC50 =0 μM) or to the combination of the latter with timolol (IC50 =0.11 μM).Citation19

Jager et al had previously observed that the accumulation of PAF in the aqueous humor of rabbits was implicated by the increase of intraocular pressure. Moreover, they supported that the systemic administration of a PAF-antagonist (BN 52021) prevented the raise of intraocular pressure.Citation33 It has already been revealed that the binding of PAF with its receptor results in the activation of PLA2 and phospholipases C, D, P, and A2; releasing arachidonic acid; prostaglandin metabolites; and protein kinase C.Citation34 PAF also stimulates the expression of selective MMPs, whose levels and activity seem to be increased in the iris/ciliary body of mice with pigmentary glaucoma.Citation35,Citation36

The present study concluded that all prostaglandin analogs suspended PAF. However, bimatoprost seems to have a potent inhibitory action against PAF compared to the moderate effect of tafluprost and the weak action of latanoprost. It was also concluded that bimatoprost can efficiently eliminate the inflammatory process that takes place in glaucomatous lesions, eliminating the concentrations of PAF.

Authors contributions

All authors contributed toward data analysis, drafting and revising the paper and agree to be accountable for all aspects of the work.

Acknowledgments

No financial support was offered for the present study.

Disclosure

The authors report no conflicts of interest in this work.

References

  • ResnikoffSPascoliniDEtya’aleDGlobal data on visual impairment in the year 2002Bull World Health Organ20048284485115640920
  • QuigleyHABromanATThe number of people with glaucoma worldwide in 2010 and 2020Br J Ophthalmol20069026226716488940
  • SchmidlDSchmettererLGarhöferGPopa-CherecheanuAPharmacotherapy of glaucomaJ Ocul Pharmacol Ther2015312637725587905
  • European Glaucoma SocietyTerminology and Guidelines for Glaucoma3rd edSavonaDogma2008
  • KomotoJYamadaTWatanabeKWoodwardDFTakusagawaFProstaglandin F2alpha formation from prostaglandin H2 by prostaglandin F synthase (PGFS): crystal structure of PGFS containing bimatoprostBiochemistry20064571987199616475787
  • PolanskyJRKurtzRMAlvaradoJAWeinrebRNMitchellMDEicosanoid production and glucocorticoid regulatory mechanisms in cultured human trabecular meshwork cellsProg Clin Biol Res19893121131382508121
  • MatsumotoSYorioTMagninoPEDeSantisLPangIHEndothelin-induced changes of second messengers in cultured human ciliary muscle cellsInvest Ophthalmol Vis Sci1996376105810668631621
  • Lütjen-DrecollETammEMorphological study of the anterior segment of cynomolgus monkey eyes following treatment with prostaglandin F2 alphaExp Eye Res19884757617693197775
  • VohraRTsaiJCKolkoMThe role of inflammation in the pathogenesis of glaucomaSurv Ophthalmol201358431132023768921
  • BazanNGAllanGSignal transduction and gene expression in the eye: a contemporary view of the pro-inflammatory, anti-inflammatory and modulatory roles of prostaglandins and other bioactive lipidsSurv Ophthalmol199741Suppl 2S23S349154273
  • ChaoWOlsonMSPlatelet-activating factor: receptors and signal transductionBiochem J19932926176298391253
  • FragopoulouEIatrouCDemopoulosCACharacterization of acetyl-CoA: lyso-PAF acetyltransferase of human mesangial cellsMediators Inflamm20052005526327216258193
  • McManusLMPinckardRNPAF, a putative mediator of oral inflammationCrit Rev Oral Biol Med200011224025812002818
  • DerewendaZSDerewendaUThe structure and function of platelet-activating factor acetylhydrolasesCell Mol Life Sci1998544464559645224
  • RosenbaumJTBoneyRSSamplesJRValoneFHSynthesis of platelet activating factor by ocular tissue from inflamed eyesArch Ophthalmol199110934104132003804
  • TsouprasABChiniMMangafasNPlatelet activating factor and its basic metabolic enzymes in blood of naive HIV-infected patientsAngiology20126334335221948973
  • BradfordMMA rapid and sensitive method for the quantization of microgram quantities of protein utilizing the principle of protein-dye bindingAnal Biochem197672248254942051
  • AntonopoulouSFragopoulouEKarantonisHCEffect of traditional Greek Mediterranean meals on platelet aggregation in normal subjects and in patients with type 2 diabetes mellitusJ Med Food2006935636217004898
  • MoschosMMChatziralliIPStamatakisGPapakonstantinouVDTsatsosMDemopoulosCAIn vitro effects of anti-glaucomatous eye drops on platelet activating factor and its metabolismSemin Ophthalmol Epub2015813
  • TsouprasABFragopoulouENomikosTIatrouCAntonopoulouSDemopoulosCACharacterization of the de novo biosynthetic enzyme of platelet activating factor, DDT insensitive cholinephosphotransferase, of human mesangial cellsMediators Inflamm200720072768317710109
  • TsouprasABChiniMTsogasNAnti-platelet activating factor effects of highly active antiretroviral therapy (HAART): a new insight in the drug therapy of HIV infection?AIDS Res Hum Retroviruses2008241079108618620493
  • GimenezRAguilarJCytidine (5′) diphosphocholine induced decrease in cerebral platelet activating factor is due to inactivation of its synthesizing enzyme cholinephosphotransferase in aged ratsNeurosci Lett200129920921211165772
  • AntonopoulouSDemopoulosCAIatrouCMoustakasGZirogiannisPPlatelet activating factor acetylhydrolase (PAF-AH) in human kidneyInt J Biochem199426115711627988740
  • OtaTAiharaMNarumiyaSAraieMThe effects of prostaglandin analogues on IOP in prostanoid FP-receptor-deficient miceInvest Ophthalmol Vis Sci2005464159416316249494
  • WoodwardDFKraussAHChenJPharmacological characterization of a novel antiglaucoma agent, Bimatoprost (AGN 192024)J Pharmacol Exp Ther2003305277278512606640
  • GandolfiSSimmonsSTSturmRChenKVanDenburghAMBimatoprost Study Group 3Three-month comparison of bimatoprost and latanoprost in patients with glaucoma and ocular hypertensionAdv Ther200118311012111571823
  • KonstasAGKatsimbrisJMLallosNBoukarasGPJenkinsJNStewartWCLatanoprost 0.005% versus bimatoprost 0.03% in primary open-angle glaucoma patientsOphthalmology2005112226226615691561
  • NoeckerRSDirksMSChoplinNTBernsteinPBatoosinghALWhitcupSMBimatoprost/Latanoprost Study GroupA six-month randomized clinical trial comparing the intraocular pressure-lowering efficacy of bimatoprost and latanoprost in patients with ocular hypertension or glaucomaAm J Ophthalmol20031351556312504698
  • UusitaloHEgorovEKaarnirantaKAstakhovYRopoABenefits of switching from latanoprost to preservative-free tafluprost eye drops: a meta-analysis of two Phase IIIb clinical trialsClin Ophthalmol20161044545427041987
  • OtaTAiharaMSaekiTNarumiyaSAraieMThe IOP-lowering effects and mechanism of action of tafluprost in prostanoid receptor-deficient miceBr J Ophthalmol200791567367617124244
  • KurashimaHWatabeHSatoNAbeSIshidaNYoshitomiTEffects of prostaglandin F(2α) analogues on endothelin-1-induced impairment of rabbit ocular blood flow: comparison among tafluprost, travoprost, and latanoprostExp Eye Res201091685385920868682
  • YamadaHYonedaMGoshoMKatoTZakoMBimatoprost, latanoprost, and tafluprost induce differential expression of matrix metalloproteinases and tissue inhibitor of metalloproteinasesBMC Ophthalmol2016162626956170
  • JagerGVvan DelftJLvan HaeringenNJVerbeijNLBraquetPAntagonist of platelet-activating factor prevents prostaglandin E2 induced ocular hypertension in rabbitsProstaglandins1993451971058424134
  • ShuklaSDPlatelet-activating factor receptor and signal transduction mechanismsFASEB J19926229623011312046
  • BazanHOttinoPThe role of platelet-activating factor in the corneal response to injuryProg Retin Eye Res20022144946412207945
  • ZhouXLiFKongLTomitaHLiCCaoWInvolvement of inflammation, degradation, and apoptosis in a mouse model of glaucomaJ Biol Chem200528035312403124815985430